Ivan Hyep Sells 9,200 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) CFO Ivan Hyep sold 9,200 shares of the company’s stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $20.42, for a total transaction of $187,864.00. Following the completion of the sale, the chief financial officer directly owned 145,355 shares of the company’s stock, valued at approximately $2,968,149.10. This trade represents a 5.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ivan Hyep also recently made the following trade(s):

• On Tuesday, April 21st, Ivan Hyep sold 9,200 shares of Bicara Therapeutics stock. The stock was sold at an average price of $23.00, for a total transaction of $211,600.00.
• On Monday, March 23rd, Ivan Hyep sold 9,200 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.52, for a total transaction of $170,384.00.
• On Wednesday, March 4th, Ivan Hyep sold 2,963 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.25, for a total transaction of $54,074.75.
• On Tuesday, March 3rd, Ivan Hyep sold 13,555 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.22, for a total transaction of $246,972.10.

Bicara Therapeutics Stock Up 1.4%

Shares of NASDAQ BCAX traded up $0.30 during midday trading on Tuesday, reaching $21.98. 555,042 shares of the company’s stock traded hands, compared to its average volume of 526,260. The stock’s 50 day simple moving average is $21.17 and its 200-day simple moving average is $18.39. Bicara Therapeutics Inc. has a one year low of $8.48 and a one year high of $24.25. The company has a market cap of $1.44 billion, a price-to-earnings ratio of -7.91 and a beta of -0.57.

Bicara Therapeutics (NASDAQ:BCAX) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.93) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.21). Equities analysts predict that Bicara Therapeutics Inc. will post -3.37 EPS for the current fiscal year.

Institutional Trading of Bicara Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in BCAX. Legal & General Group Plc grew its stake in Bicara Therapeutics by 64.1% during the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock worth $29,000 after buying an additional 1,233 shares during the last quarter. Tower Research Capital LLC TRC raised its stake in Bicara Therapeutics by 419.3% in the second quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock valued at $44,000 after buying an additional 3,866 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Bicara Therapeutics in the fourth quarter valued at about $45,000. Larson Financial Group LLC boosted its holdings in Bicara Therapeutics by 1,015.5% in the third quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock worth $62,000 after acquiring an additional 3,595 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd grew its stake in shares of Bicara Therapeutics by 385.3% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 5,775 shares of the company’s stock worth $97,000 after acquiring an additional 4,585 shares during the last quarter.

Analyst Upgrades and Downgrades

Several research firms have recently commented on BCAX. Guggenheim assumed coverage on Bicara Therapeutics in a research report on Monday, May 11th. They issued a “buy” rating and a $42.00 price target for the company. Wall Street Zen upgraded Bicara Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Sunday. Bank of America initiated coverage on shares of Bicara Therapeutics in a report on Wednesday, March 25th. They issued a “buy” rating and a $35.00 target price for the company. Wells Fargo & Company increased their price target on shares of Bicara Therapeutics from $11.00 to $16.00 and gave the company an “equal weight” rating in a research report on Tuesday, March 31st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Bicara Therapeutics in a report on Wednesday, April 8th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Bicara Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $30.27.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.